Longeveron (NASDAQ:LGVN – Get Free Report) and Marker Therapeutics (NASDAQ:MRKR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.
Valuation & Earnings
This table compares Longeveron and Marker Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longeveron | $1.20 million | 5.72 | -$22.70 million | ($9.90) | -0.22 |
| Marker Therapeutics | $3.55 million | 4.34 | -$12.16 million | ($0.41) | -2.26 |
Institutional & Insider Ownership
10.0% of Longeveron shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 7.4% of Longeveron shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Longeveron has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.
Profitability
This table compares Longeveron and Marker Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
| Marker Therapeutics | N/A | -56.96% | -47.82% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Longeveron and Marker Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
| Marker Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Longeveron currently has a consensus price target of $80.00, indicating a potential upside of 3,620.93%. Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 981.20%. Given Longeveron’s higher possible upside, equities research analysts plainly believe Longeveron is more favorable than Marker Therapeutics.
Summary
Marker Therapeutics beats Longeveron on 10 of the 14 factors compared between the two stocks.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
About Marker Therapeutics
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
